| Trial ID: | L0402 |
| Source ID: | NCT04686994
|
| Associated Drug: |
ASC41
|
| Title: |
A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics (Biomarkers) of ASC41 Tables in Overweight and Obese Subjects
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Overweight and Obesity;NAFLD;Hyperlipidemia
|
| Interventions: |
Drug: ASC 41;Drug: ASC 41 Placebo
|
| Outcome Measures: |
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]AUC of ASC41;Cmax of ASC41;t1/2 of ASC41;CL/F of ASC41;Vd/F of ASC41;Tmax of ASC41;LDL-C and other lipid parameters
|
| Sponsor/Collaborators: |
Gannex Pharma Co., Ltd.
|
| Gender: |
All
|
| Age: |
18 Years59 Years
|
| Phases: |
Phase 1
|
| Enrollment: |
20
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
|
| Start Date: |
23/12/2020
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
19 April 2021
|
| Locations: |
China
|
| URL: |
https://clinicaltrials.gov/show/NCT04686994
|
